Please assess the completion status of the following clinical trial:

Trial Title: Evaluating the Renoprotective Effect of Milk Thistle Extract on Patients With Type II Diabetic Nephropathy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Type II diabetes~* Overt proteinuria defined by urinary albumin excretion \> 300 mg/24 hr in 2 consecutive determinations despite treatment with highest FDA recommended doses of an angiotensin converting enzyme inhibitor or angiotensin receptor blocker for at least 6 months.~* Treatment of hyperglycemia with (but not limited to) an oral hypoglycemic agent or insulin (If a thiazolidinedione is used, stable dose for at least 6 months)~* Treatment of hypercholesterolemia with (but not limited to) one medication from the class statins~* Presence of diabetic retinopathy~* Signing informed consent~Exclusion Criteria:~* Type I diabetes~* Advanced chronic kidney disease defined by estimated GFR \< 30 ml/min/1.73 m2~* Severely uncontrolled diabetes defined by HbA1C \> 10%~* Uncontrolled hypertension defined by SBP \>160 mmHg or DBP \>100 mmHg despite antihypertensive therapy~* Secondary forms of hypertension with defined etiology other than diabetes mellitus~* Other renal diseases~* History of solid organ transplantation~* Chronic Heart Failure with NYHA class III or IV~* Active infection~* Pregnancy~* Use of one of the following medications within 2 months prior to enrollment in the study:~  * Non-steroidal anti-inflammatory agents~ * Antioxidants supplements including: vitamin E, vitamin C, N-acetyl- cysteine (NAC), Pentoxyfilline, Lipoic acid, Fish-oil extracts (omega-3 fatty acids), Soy extracts (isoflavones), Green-tea preparations, Pomegranate extracts, Grape extracts~* Active malignancy~* Hepatitis virus or Human Immunodeficiency virus infections~* History of drug or alcohol dependency~* Cigarette smoking~* Psychiatric or neurological condition, preventing aware consent to the study and/or adherence to the study protocol

- Gender: ALL
- Minimum Age: 30 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- placebo (Type: PLACEBO_COMPARATOR): 1 tablet 3 times daily
- Milk Thistle extract (Type: EXPERIMENTAL): 1 tablet of the extract (equivalent to 140 mg silymarin) 3 times per day

Based on this trial design, predict the completion outcome and termination type (if applicable).